Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 1
1971 1
1972 1
1973 2
1974 2
1975 1
1977 1
1978 2
1980 2
1986 2
1995 2
1996 1
1997 2
1998 1
1999 1
2001 1
2005 2
2006 3
2007 10
2008 7
2009 7
2010 6
2011 5
2012 7
2013 14
2014 13
2015 6
2016 9
2017 12
2018 11
2019 7
2020 7
2021 7
2022 16
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer.
Tintelnot J, Xu Y, Lesker TR, Schönlein M, Konczalla L, Giannou AD, Pelczar P, Kylies D, Puelles VG, Bielecka AA, Peschka M, Cortesi F, Riecken K, Jung M, Amend L, Bröring TS, Trajkovic-Arsic M, Siveke JT, Renné T, Zhang D, Boeck S, Strowig T, Uzunoglu FG, Güngör C, Stein A, Izbicki JR, Bokemeyer C, Sinn M, Kimmelman AC, Huber S, Gagliani N. Tintelnot J, et al. Among authors: boeck s. Nature. 2023 Mar;615(7950):168-174. doi: 10.1038/s41586-023-05728-y. Epub 2023 Feb 22. Nature. 2023. PMID: 36813961 Free PMC article.
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Kunzmann V, et al. Among authors: boeck s. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
Novel systemic treatment approaches for metastatic pancreatic cancer.
Dorman K, Heinemann V, Kobold S, von Bergwelt-Baildon M, Boeck S. Dorman K, et al. Among authors: boeck s. Expert Opin Investig Drugs. 2022 Mar;31(3):249-262. doi: 10.1080/13543784.2022.2037552. Epub 2022 Feb 10. Expert Opin Investig Drugs. 2022. PMID: 35114868 Review.
[Treatment of metastatic pancreatic cancer].
Heinemann V, Boeck S, Westphalen CB. Heinemann V, et al. Among authors: boeck s. Inn Med (Heidelb). 2022 Aug;63(8):851-862. doi: 10.1007/s00108-022-01334-8. Epub 2022 Jul 6. Inn Med (Heidelb). 2022. PMID: 35925070 German.
Advances in cancer immunotherapy 2019 - latest trends.
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. Kruger S, et al. Among authors: boeck s. J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. J Exp Clin Cancer Res. 2019. PMID: 31217020 Free PMC article. Review.
Systemic treatment of advanced pancreatic cancer.
Heinemann V, Haas M, Boeck S. Heinemann V, et al. Among authors: boeck s. Cancer Treat Rev. 2012 Nov;38(7):843-53. doi: 10.1016/j.ctrv.2011.12.004. Epub 2012 Jan 4. Cancer Treat Rev. 2012. PMID: 22226241 Review.
Safety of palliative chemotherapy in advanced pancreatic cancer.
Westphalen CB, Kruger S, Haas M, Heinemann V, Boeck S. Westphalen CB, et al. Among authors: boeck s. Expert Opin Drug Saf. 2016 Jul;15(7):947-54. doi: 10.1080/14740338.2016.1177510. Epub 2016 May 3. Expert Opin Drug Saf. 2016. PMID: 27070177 Review.
Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma.
Hoffmeister-Wittmann P, Mock A, Nichetti F, Korell F, Heilig CE, Scherr AL, Günther M, Albrecht T, Kelmendi E, Xu K, Nader L, Kessler A, Schmitt N, Fritzsche S, Weiler S, Sobol B, Stenzinger A, Boeck S, Westphalen CB, Schulze-Osthoff K, Trojan J, Kindler T, Weichert W, Spiekermann K, Bitzer M, Folprecht G, Illert AL, Boerries M, Klauschen F, Ochsenreither S, Siveke J, Bauer S, Glimm H, Brors B, Hüllein J, Hübschmann D, Uhrig S, Horak P, Kreutzfeldt S, Banales JM, Springfeld C, Jäger D, Schirmacher P, Roessler S, Ormanns S, Goeppert B, Fröhling S, Köhler BC. Hoffmeister-Wittmann P, et al. Among authors: boeck s. Liver Int. 2022 Dec;42(12):2855-2870. doi: 10.1111/liv.15392. Epub 2022 Sep 14. Liver Int. 2022. PMID: 35983950 Free article.
Oligometastatic Disease in Pancreatic Cancer - How to Proceed?
Renz BW, Boeck S, Roeder F, Trumm C, Heinemann V, Werner J. Renz BW, et al. Among authors: boeck s. Visc Med. 2017 Mar;33(1):36-41. doi: 10.1159/000455027. Epub 2017 Feb 10. Visc Med. 2017. PMID: 28612015 Free PMC article. Review.
Sequence therapy in metastatic pancreatic cancer.
Waidmann O, Pelzer U, Boeck S, Waldschmidt DT. Waidmann O, et al. Among authors: boeck s. Z Gastroenterol. 2018 Jun;56(6):578-582. doi: 10.1055/a-0581-5640. Epub 2018 Jun 11. Z Gastroenterol. 2018. PMID: 29890560 English.
167 results